ClinicalTrials.gg
Sign In
CompletedNCT03453060Updated Oct 29, 2019Results posted

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

A Phase 1 interventional study of E-WE Thrombin- Dose 1 and E-WE Thrombin- Dose 2 in Thrombosis, sponsored by Aronora, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by Aronora, Inc. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacodynamics of a single iv dose of E-WE Thrombin in healthy adult subjects.

02

Conditions studied

  • Thrombosis

Browse trials for

03

In context

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

This study's enrollment of 21 is below the median of 83 across 530 interventional studies indexed under Thrombosis.

Browse Thrombosis studies →

Lead sponsor

Aronora, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male and/or female (females of non- only), 18 to 55 years of age, inclusive, at screening.
  2. Continuous non-smoker, who has not used nicotine-containing products for at least 3 months prior to dosing, based on subject self-reporting.
  3. (BMI) ≥ 18 and \< 29 (kg/m2) at screening and weight between 50 and 125 kg (inclusive) at screening.
  4. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or , as deemed by the PI or designee.

  5. A female must be of non childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to dosing:

    • hysteroscopic sterilization;
    • bilateral tubal ligation or bilateral salpingectomy;
    • hysterectomy;
    • bilateral oophorectomy. or be with amenorrhea for at least 1 year prior to dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.
  6. A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to dosing of study drug. A male who has been vasectomized less than 4 months prior to dosing must follow the same restrictions as a non vasectomized male).
  7. If male, must agree to not donate sperm from dosing until 90 days after dosing.
  8. Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.
  3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  4. History or presence of alcoholism or drug abuse within the past 2 years prior to dosing.
  5. Consumes 3 units or more of alcohol per day (e.g., 1 unit is equivalent to 240 mL of wine, 1 bottle of beer [12 oz.], or 1 shot of liquor [1 oz.]).
  6. History or presence of or idiosyncratic reaction to the study drug and or related compounds.

  7. History or presence of a disease or disorder, acquired or inherited, that is active, or could be reasonably expected to become active during the study, including but not limited to:

    • Hypersensitivity to ß-lactam / penicillin derivatives;
    • Bleeding and blood coagulation disorders, including stroke, hemophilias, thrombophilias, or heparin-induced thrombocytopenia;
    • Ischemic disorders, including stroke, heart attack, coronary artery disease;
    • Gastrointestinal disorders, including gastrointestinal bleeds, gallstones, ulcers, diseases or dysfunction of the liver and excluding appendectomy and/or cholecystectomy;
    • Genitourinary disorders, including renal disease;
    • Cardiovascular disorders, including aneurysms, vasculitis;
    • All conditions that are associated with taking medications for pain;
    • Infection of any organ or system within 30 days of dosing;
    • Malignant and cancerous neoplasms of any organ or system;
    • Psychiatric and behavioral disorders;
    • A clinically significant hematological disorder of any type;
    • Inflammation and inflammatory diseases of any organ system.
  8. Females of .
  9. Females who are pregnant or who are lactating.
  10. Positive urine drug or alcohol results at screening or check in.
  11. Positive results at screening for (HIV), surface antigen (HBsAg), or antibodies (HCV).
  12. Supine blood pressure is less than 90/50 mmHg or greater than 140/90 mmHg at screening.
  13. Supine heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  14. interval > 450 msec for males or > 460 msec for females, or history of prolonged QT syndrome at screening.
  15. Estimated \< 90 mL/minutes at screening using the Cockcroft Gault estimation.

  16. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to dosing and throughout the study.
    • Any oral or injectable anticoagulant (e.g., warfarin, heparin, low molecular weight heparin, etc.), coagulants (aprotinin, tranexamic acid, epsilon-aminocaproic acid, and aminomethylbenzoic acid), anti- (e.g., clopidogrel), nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetylsalicylic acid (ASA) beginning approximately 10 days prior to dosing and throughout the study.
    • Any drugs known to be significant inducers of cytochrome P-450 enzymes and/or P glycoprotein, including St. John's Wort, for 28 days prior to dosing and throughout the study.

    Appropriate sources (e.g., Flockhart TableTM) will be consulted to confirm lack of pharmacokinetic/ pharmacodynamic interaction with study medication. Acetaminophen (up to 2 g per 24 hour period) or any other treatment of an adverse event, drug related or not, and considered appropriate and allowable by the PI or designee may be permitted after dosing.

  17. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 30 days prior to dosing and throughout the study.
  18. Has participated in strenuous exercise or physical activity within 72 hours prior to Day 1, unless deemed acceptable by the PI or designee.
  19. Donation of blood or significant blood loss within 56 days prior to dosing.
  20. Plasma donation within 7 days prior to dosing.
  21. Has been hospitalized within 2 months of Day -1.
  22. Participation in another clinical study within 30 days prior to dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study.
  23. Surgery within the past 90 days prior to dosing which in the opinion of the PI or designee is clinically relevant.
  24. Presence of any scars, or tattoos which may obscure the injection site, as deemed by PI or designee.
  25. Any condition or circumstance, in the opinion of the PI or designee, which may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    E-WE Thrombin Dose 1

    Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.

    Drug: E-WE Thrombin- Dose 1

  • Experimental
    E-WE Thrombin Dose 2

    Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.

    Drug: E-WE Thrombin- Dose 2

  • Experimental
    E-WE Thrombin Dose 3

    Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.

    Drug: E-WE Thrombin- Dose 3

  • Experimental
    E-WE Thrombin Dose 4

    Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.

    Drug: E-WE Thrombin- Dose 4

  • Placebo comparator
    Placebo

    Participants will receive a single intravenous dose of placebo.

    Other: Placebo

Interventions

  • DrugE-WE Thrombin- Dose 1

    Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.

    Also known as: AB002- Dose 1

  • DrugE-WE Thrombin- Dose 2

    Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.

    Also known as: AB002- Dose 2

  • DrugE-WE Thrombin- Dose 3

    Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.

    Also known as: AB002- Dose 3

  • DrugE-WE Thrombin- Dose 4

    Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.

    Also known as: AB002- Dose 4

  • OtherPlacebo

    Participants received a single intravenous dose of placebo.

06

What researchers measure

Primary outcomes

  1. The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.

    TEAEs will be determined by symptom driven physical examinations that can include assessment of the skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.

    Time frame: one month

  2. The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.

    Body temperature will be measured in degrees Celsius. Clinically significant changes in body temperature are determined by the PI or designee.

    Time frame: two days

  3. The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.

    Respiratory rate will be measured in breaths per minute. Clinically significant changes in respiratory rate are determined by the PI.

    Time frame: two days

  4. The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.

    Systolic and diastolic blood pressure will be measured in mmHg. Clinically significant changes in systolic and diastolic blood pressure are determined by the PI or designee.

    Time frame: two days

  5. The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.

    Heart rate will be measured in beats per minute. Clinically significant changes in heart rate are determined by the PI or designee.

    Time frame: two days

  6. The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment.

    12-lead electrocardiogram measurement. Abnormal electrocardiograms are determined by the PI or designee.

    Time frame: two days

  7. The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

    Plasma aPTT will be measured in seconds. Clinically significant changes in aPTT are determined by the PI or designee.

    Time frame: one month

  8. The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

    Prothrombin time will be measured in seconds. Clinically significant changes in prothrombin time are determined by the PI or designee.

    Time frame: one month

  9. The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

    Thrombin time will be measured in seconds. Clinically significant changes in thrombin time are determined by the PI or designee.

    Time frame: one month

  10. The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

    Plasma fibrinogen levels will be measured in mg/dL. Clinically significant changes in plasma fibrinogen levels are determined by the PI or designee.

    Time frame: one month

  11. The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment.

    Injection site reaction assessment (pain, tenderness, erythema/ redness, and induration/ swelling.

    Time frame: two days

  12. The Number of Subjects That Develop Treatment-related Immunogenicity.

    Immunogenicity measured by plasma anti-drug antibodies.

    Time frame: one month

  13. The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed.

    BUN levels in the blood will be measured in mg/dL. Clinically significant changes in BUN are determined by the PI or designee.

    Time frame: two days

  14. The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Bilirubin (total and direct) levels in the blood will be measured in mg/dL. Clinically significant changes in total and direct bilirubin levels are determined by the PI or designee.

    Time frame: two days

  15. The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Alkaline phosphatase levels in the blood will be measured in U/L. Clinically significant changes in alkaline phosphatase levels are determined by the PI or designee.

    Time frame: two days

  16. The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    AST levels in the blood will be measured in U/L. Clinically significant changes in AST levels are determined by the PI or designee.

    Time frame: two days

  17. The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    ALT levels in the blood will be measured in U/L. Clinically significant changes in ALT levels are determined by the PI or designee.

    Time frame: two days

  18. The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    LDH levels in the blood will be measured in U/L. Clinically significant changes in LDH levels are determined by the PI or designee.

    Time frame: two days

  19. The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Albumin levels in the blood will be measured in g/dL. Clinically significant changes in albumin levels are determined by the PI or designee.

    Time frame: two days.

  20. The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Sodium levels will be measured in mEq/L. Clinically significant changes in sodium levels are determined by the PI or designee.

    Time frame: two days

  21. The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Potassium levels will be measured in mEq/L. Clinically significant changes in potassium levels are determined by the PI or designee.

    Time frame: two days

  22. The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Chloride levels will be measured in mEq/L. Clinically significant changes in chloride levels are determined by the PI or designee.

    Time frame: two days

  23. The Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Bicarbonate levels will be measured in mEq/L. Clinically significant changes in bicarbonate levels are determined by the PI or designee.

    Time frame: two days

  24. The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Blood glucose levels will be measured in mg/dL. Clinically significant changes in blood glucose levels are determined by the PI or designee.

    Time frame: two days

  25. The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

    Creatinine levels will be measured in mg/dL. Clinically significant changes in creatinine levels are determined by the PI or designee.

    Time frame: two days

  26. The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Hemoglobin levels will be measured in g/dL. Clinically significant changes in hemoglobin levels are determined by the PI or designee.

    Time frame: two days

  27. The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Hematocrit levels will be measured in %. Clinically significant changes in hematocrit levels are determined by the PI or designee.

    Time frame: two days

  28. The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Total leukocyte counts will be measured in 10˄3/uL. Clinically significant changes in leukocyte counts are determined by the PI or designee.

    Time frame: two days.

  29. The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Differential leukocyte counts will be measured in %. Clinically significant changes in differential leukocyte counts are determined by the PI or designee.

    Time frame: two days.

  30. The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Red blood cell count will be measured in 10˄6/uL. Clinically significant changes in red blood cell counts are determined by the PI or designee.

    Time frame: two days

  31. The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

    Platelet count will be measured in 10˄3/uL. Clinically significant changes in platelet counts are determined by the PI or designee.

    Time frame: two days

  32. The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    pH of the urine will be measured. Clinically significant changes in urine pH are determined by the PI or designee.

    Time frame: two days

  33. The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Specific gravity of the urine will be evaluated. Clinically significant changes in specific gravity are determined by the PI or designee.

    Time frame: two days

  34. The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Protein levels in the urine will be evaluated. Clinically significant changes in protein levels are determined by the PI or designee.

    Time frame: two days

  35. The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Glucose levels in the urine will be evaluated. Clinically significant changes in urine glucose are determined by the PI or designee.

    Time frame: two days

  36. The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Ketone levels in the urine will be evaluated. Clinically significant changes in urine ketone levels are determined by the PI or designee.

    Time frame: two days

  37. The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Bilirubin levels in the urine will be evaluated. Clinically significant changes in urine bilirubin levels are determined by the PI or designee.

    Time frame: two days

  38. The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Blood levels in the urine will be evaluated. Clinically significant changes in urine blood levels are determined by the PI or designee.

    Time frame: two days

  39. The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Nitrite levels in the urine will be evaluated. Clinically significant changes in urine nitrite levels are determined by the PI or designee.

    Time frame: two days

  40. The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Urobilinogen levels in the urine will be evaluated. Clinically significant changes in urine urobilinogen levels are determined by the PI or designee.

    Time frame: two days

  41. The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

    Leukocyte esterase levels in the urine will be evaluated. Clinically significant changes in urine leukocyte esterase levels are determined by the PI or designee.

    Time frame: two days

Secondary outcomes

  1. The Effect of a Single Intravenous Dose of E-WE Thrombin on Generation of Activated Protein C- Protein C Inhibitor Complexes (APC-PCI).

    Plasma APC-PCI levels will be measured in ng/mL.

    Time frame: Predose, 0.08, 0.25, 0.5, 1, 2, 4, and 24h post-dose

07

Results

Posted Oct 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
Started44445
Completed44445
Not completed00000

Outcome measures

PrimaryThe Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.

TEAEs will be determined by symptom driven physical examinations that can include assessment of the skin, head, ears, eyes, nose, throat, respiratory system, cardiovascular system, gastrointestinal system, neurological condition, blood and lymphatic systems, and the musculoskeletal system.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts.00031
PrimaryThe Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.

Body temperature will be measured in degrees Celsius. Clinically significant changes in body temperature are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Body Temperature, Frequency, and Relation to Treatment Will be Assessed.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.

Respiratory rate will be measured in breaths per minute. Clinically significant changes in respiratory rate are determined by the PI.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Respiratory Rate, Frequency, and Relation to Treatment Will be Assessed.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.

Systolic and diastolic blood pressure will be measured in mmHg. Clinically significant changes in systolic and diastolic blood pressure are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Blood Pressure (Systolic and Diastolic), Frequency, and Relation to Treatment Will be Assessed.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.

Heart rate will be measured in beats per minute. Clinically significant changes in heart rate are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Heart Rate, Frequency, and Relation to Treatment Will be Assessed.00000
PrimaryThe Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment.

12-lead electrocardiogram measurement. Abnormal electrocardiograms are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Abnormal Electrocardiogram and Frequency and/ or Adverse Events That Are Related to Treatment.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

Plasma aPTT will be measured in seconds. Clinically significant changes in aPTT are determined by the PI or designee.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Activated Partial Thromboplastin Time (aPTT), Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

Prothrombin time will be measured in seconds. Clinically significant changes in prothrombin time are determined by the PI or designee.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Prothrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

Thrombin time will be measured in seconds. Clinically significant changes in thrombin time are determined by the PI or designee.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Thrombin Time, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.

Plasma fibrinogen levels will be measured in mg/dL. Clinically significant changes in plasma fibrinogen levels are determined by the PI or designee.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Plasma Fibrinogen, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Coagulation Panel.00000
PrimaryThe Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment.

Injection site reaction assessment (pain, tenderness, erythema/ redness, and induration/ swelling.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Injection Site Reaction and/ or Adverse Events That Are Related to Treatment.00000
PrimaryThe Number of Subjects That Develop Treatment-related Immunogenicity.

Immunogenicity measured by plasma anti-drug antibodies.

Time frame:
one month
Reported as:
Count of participants · Participants
The Number of Subjects That Develop Treatment-related Immunogenicity.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects That Develop Treatment-related Immunogenicity.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed.

BUN levels in the blood will be measured in mg/dL. Clinically significant changes in BUN are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Blood Urea Nitrogen Levels (BUN) as Part of a Standard Serum Chemistry Panel, Frequency, and Relation to Treatment Will be Assessed.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Bilirubin (total and direct) levels in the blood will be measured in mg/dL. Clinically significant changes in total and direct bilirubin levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Bilirubin (Total and Direct) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Alkaline phosphatase levels in the blood will be measured in U/L. Clinically significant changes in alkaline phosphatase levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Alkaline Phosphatase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

AST levels in the blood will be measured in U/L. Clinically significant changes in AST levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Aspartate Aminotransferase (AST) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

ALT levels in the blood will be measured in U/L. Clinically significant changes in ALT levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Alanine Aminotransferase (ALT) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

LDH levels in the blood will be measured in U/L. Clinically significant changes in LDH levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Lactate Dehydrogenase (LDH) Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Albumin levels in the blood will be measured in g/dL. Clinically significant changes in albumin levels are determined by the PI or designee.

Time frame:
two days.
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Albumin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Sodium levels will be measured in mEq/L. Clinically significant changes in sodium levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Sodium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Potassium levels will be measured in mEq/L. Clinically significant changes in potassium levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Potassium Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Chloride levels will be measured in mEq/L. Clinically significant changes in chloride levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Chloride Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Bicarbonate levels will be measured in mEq/L. Clinically significant changes in bicarbonate levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Bicarbonate Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Blood glucose levels will be measured in mg/dL. Clinically significant changes in blood glucose levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.

Creatinine levels will be measured in mg/dL. Clinically significant changes in creatinine levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Creatinine Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Serum Chemistry Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Hemoglobin levels will be measured in g/dL. Clinically significant changes in hemoglobin levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Hemoglobin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Hematocrit levels will be measured in %. Clinically significant changes in hematocrit levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Hematocrit Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Total leukocyte counts will be measured in 10˄3/uL. Clinically significant changes in leukocyte counts are determined by the PI or designee.

Time frame:
two days.
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Total Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Differential leukocyte counts will be measured in %. Clinically significant changes in differential leukocyte counts are determined by the PI or designee.

Time frame:
two days.
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Differential Leukocyte Counts, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Red blood cell count will be measured in 10˄6/uL. Clinically significant changes in red blood cell counts are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Red Blood Cell Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.

Platelet count will be measured in 10˄3/uL. Clinically significant changes in platelet counts are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Platelet Count, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Hematology Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

pH of the urine will be measured. Clinically significant changes in urine pH are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine pH, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Specific gravity of the urine will be evaluated. Clinically significant changes in specific gravity are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Specific Gravity, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Protein levels in the urine will be evaluated. Clinically significant changes in protein levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Protein Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Glucose levels in the urine will be evaluated. Clinically significant changes in urine glucose are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Glucose Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Ketone levels in the urine will be evaluated. Clinically significant changes in urine ketone levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Ketone Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Bilirubin levels in the urine will be evaluated. Clinically significant changes in urine bilirubin levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Bilirubin Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Blood levels in the urine will be evaluated. Clinically significant changes in urine blood levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Blood Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Nitrite levels in the urine will be evaluated. Clinically significant changes in urine nitrite levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Nitrite Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Urobilinogen levels in the urine will be evaluated. Clinically significant changes in urine urobilinogen levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Urobilinogen Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
PrimaryThe Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.

Leukocyte esterase levels in the urine will be evaluated. Clinically significant changes in urine leukocyte esterase levels are determined by the PI or designee.

Time frame:
two days
Reported as:
Count of participants · Participants
The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.
ParticipantsE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
The Number of Subjects With Clinically Significant Changes in Urine Leukocyte Esterase Levels, Frequency, and Relation to Treatment Will be Assessed as Part of a Standard Urinalysis Panel.00000
SecondaryThe Effect of a Single Intravenous Dose of E-WE Thrombin on Generation of Activated Protein C- Protein C Inhibitor Complexes (APC-PCI).

Plasma APC-PCI levels will be measured in ng/mL.

Time frame:
Predose, 0.08, 0.25, 0.5, 1, 2, 4, and 24h post-dose
Reported as:
Mean · ng/mL
The Effect of a Single Intravenous Dose of E-WE Thrombin on Generation of Activated Protein C- Protein C Inhibitor Complexes (APC-PCI).
ng/mLE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
predose1.8 ± 0.91.3 ± 0.72.0 ± 0.71.0 ± 0.01.5 ± 0.7
0.08 hours post dose61.8 ± 16.3123.0 ± 5.0195.3 ± 16.8283.3 ± 61.21.7 ± 0.9
0.25 hours post dose108.2 ± 20.5218.3 ± 4.6364.8 ± 86.4579.0 ± 82.01.2 ± 0.5
0.5 hours post dose122.0 ± 18.6229.8 ± 19.4470.8 ± 140.9678.3 ± 84.81.3 ± 0.6
1 hour post dose90.9 ± 12.9194.5 ± 24.2328.8 ± 94.0480.5 ± 33.61.2 ± 0.5
2 hours post dose27.3 ± 3.856.2 ± 14.8124.5 ± 40.4132.3 ± 17.41.2 ± 0.5
4 hours post dose3.5 ± 0.55.9 ± 1.312.7 ± 6.215.2 ± 4.31.0 ± 0.0
24 hours post dose1.0 ± 0.01.0 ± 0.01.7 ± 0.91.0 ± 0.01.6 ± 0.8

Adverse events

Collected over Adverse events were recorded from subject check-in through follow up which occurred on Day 28.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E-WE Thrombin Dose 10/4 (0%)0/4 (0%)0/4 (0%)
E-WE Thrombin Dose 20/4 (0%)0/4 (0%)0/4 (0%)
E-WE Thrombin Dose 30/4 (0%)0/4 (0%)0/4 (0%)
E-WE Thrombin Dose 40/4 (0%)0/4 (0%)3/4 (75%)
Placebo0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent other events
Most frequent other events
EventE-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4Placebo
HeadacheNervous system disorders0/40/40/42/40/5
Vessel puncture site haemorrhageGeneral disorders0/40/40/41/40/5
InsomniaPsychiatric disorders0/40/40/41/40/5
Back painMusculoskeletal and connective tissue disorders0/40/40/40/41/5
PruritusSkin and subcutaneous tissue disorders0/40/40/40/41/5
Rash papularSkin and subcutaneous tissue disorders0/40/40/40/41/5
Skin exfoliationSkin and subcutaneous tissue disorders0/40/40/40/41/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)E-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4PlaceboTotal
Mean44.0 (40 to 52)37.3 (26 to 47)33.8 (23 to 46)36.0 (23 to 52)43.0 (33 to 53)39.0 (23 to 53)
Sex: Female, Male
Sex: Female, Male(Participants)E-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4PlaceboTotal
Female3223414
Male122117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4PlaceboTotal
Hispanic or Latino3423416
Not Hispanic or Latino102115
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)E-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4PlaceboTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American101002
White3334518
More than one race010001
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)E-WE Thrombin Dose 1E-WE Thrombin Dose 2E-WE Thrombin Dose 3E-WE Thrombin Dose 4PlaceboTotal
United States4444521
08

Study locations

1 site
  • Celerion
    Tempe, Arizona 85283, United States
09

References and documents

Publications

  • Tucker EI, Verbout NG, Markway BD, Wallisch M, Lorentz CU, Hinds MT, Shatzel JJ, Pelc LA, Wood DC, McCarty OJT, Di Cera E, Gruber A. The protein C activator AB002 rapidly interrupts thrombus development in baboons. Blood. 2020 Feb 27;135(9):689-699. doi: 10.1182/blood.2019002771. PubMed 31977000 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03453060
Lead sponsor
Aronora, Inc.
Responsible party
Sponsor
First posted
Mar 5, 2018
Start date
May 30, 2018
Primary completion
Nov 25, 2018
Completion
Nov 25, 2018
Results posted
Oct 29, 2019
Last update
Oct 29, 2019

Study contacts

Danielle Armas, MD
principal investigator · Celerion

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thrombosis →

Other studies from this sponsor

Aronora, Inc.

Start the discussion